CapsoVision's Quiet Period Ends on August 11th, Opening Door for Research Coverage

CapsoVision, Inc. (NASDAQ:CV) Announces End of Quiet Period on August 11th Market analysts anticipate that following the conclusion of CapsoVision's quiet period on August 11th, underwriters involved in the company's recent IPO will begin issuing research reports, offering investors fresh insights into the firm's prospects. The company initially offered 5.5 million shares at $5.00 each, raising $27.5 million. During the restricted quiet period, regulatory rules prevent insiders and underwriters from releasing research on the company. As the period ends, brokerage firms are expected to initiate coverage, providing the market with updated evaluations. Since its IPO on July 2nd, CapsoVision has attracted attention from various analysts. Roth Capital has set a target price of $6.00 with a buy rating, while Benchmark has issued a 'speculative buy' rating with a $5.00 target. Recently, Wall Street Zen upgraded the stock to a hold, reflecting cautious optimism. The stock opened at $3.91 and has fluctuated between $3.49 and $5.72 over the past year. CapsoVision specializes in developing advanced imaging and AI-driven solutions for gastrointestinal diagnostics, including capsule endoscop...